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Abstract Voriconazole is increasingly used as a ﬁrst-line
agent for empirical antifungal therapy of prolonged
febrile neutropenia in paediatric cancer patients. We
describe the case of a 9-year-old patient with stage IV
Burkitt lymphoma, who developed pulmonary and
splenic zygomycosis while receiving voriconazole for
persistent febrile neutropenia. The causative agent,
Absidia corymbifera, was identiﬁed by broad-range
fungal PCR in a lung biopsy sample. The patient was
successfully treated with a combination of partial
resection of the left upper lobe and antifungal therapy
with high-dose liposomal amphotericin B followed by
oral itraconazole as demonstrated by resolving pulmo-
nary inﬁltrates on serial high resolution CT scans.
Conclusion: This case emphasises that the lack of in vitro
activity of voriconazole against zygomycetes is clinically
relevant. Failure of voriconazole in suspected fungal
infection should be investigated for the possibility of
zygomycosis. Broad-range polymerase chain reaction
may be able to identify the causative organism when
cultures remain sterile.
Keywords Absidia corymbifera Æ Broad-range
polymerase chain reaction Æ Mucor Æ Voriconazole Æ
Zygomycosis
Abbreviations BAL: bronchoalveolar lavage Æ HRCT:
high-resolution computed tomography Æ PET:
positron emission tomography
Introduction
Febrile neutropenia is a common complication of che-
motherapy in paediatric cancer patients. Standard
management consists of broad-spectrum antibacterial
therapy [7] and, if fever and neutropenia persist for more
than 5 to 7 days, of antifungal therapy [7]. This strategy
is based on the high risk of invasive fungal disease in
prolonged febrile neutropenia, poor sensitivity of diag-
nostic procedures, and high case-fatality rate [6].
Amphotericin B has almost always been the drug of
choice for empirical antifungal therapy; however,
the disadvantages of conventional amphotericin B
(infusion-related adverse events, nephrotoxicity, poor
oral bioavailability) led to the development of new
broad-spectrum antifungal agents, which include lipid
formulations of amphotericin B, the echinocandins and
new triazoles. Among the latter, voriconazole is of
particular interest. Clinical trials in adults indicated
comparable eﬃcacy and a lower rate of adverse events in
comparison with liposomal amphotericin B in neutro-
penia and persistent fever [17]. In addition, voriconazole
can be administered orally. It is thus an attractive
alternative to amphotericin B for empirical antifungal
therapy in children, although no comparative trials have
been conducted in this age group, and the clinical
relevance of genetically determined variation of vorico-
nazole metabolism has not been clariﬁed [16]. Another
potential disadvantage is the lack of antifungal
activity against zygomycetes. Indeed, breakthrough
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zygomycoses have recently been reported in adults
receiving voriconazole [2, 10, 12]. This is the ﬁrst report
of voriconazole failure in a child with disseminated
zygomycosis.
Case report
A 9-year-old girl with stage IV Burkitt lymphoma
diagnosed 5 months earlier developed fever after the last
course of chemotherapy with methotrexate, cytarabine
and dexamethasone (10 mg/m2 per day for 5 days). On
physical examination, temperature was 40.2C, heart
rate was 100 bpm, blood pressure was 100/60 mmHg,
and O2 saturation was 96%. There was a small skin
papule at a former venipuncture site on the dorsum of
the right hand. No other source of fever was found.
Laboratory evaluation revealed a WBC of 0.1·109/l, a
platelet count of 11·109/l, and a CRP level of 26 mg/l.
At that time, she had been severely neutropenic (WBC
<0.5·109/l) for 17 days. Empirical therapy with cefe-
pime and amikacin was started. Routine blood cultures
grew Enterobacter cloacae and a-haemolytic strepto-
cocci. On day 6 of persistent fever, the WBC was
0.3·109/l, the platelet count was 30·109/l, and the CRP
level had risen to 158 mg/l. A chest X-ray ﬁlm showed a
parenchymal consolidation in the left upper lobe sug-
gestive of pneumonia and one of two blood cultures
grew coagulase-negative staphylococci. Since these
blood cultures were drawn from a central line and
growth was reported after 60 h of incubation only,
contamination was assumed. Nevertheless, antimicro-
bial therapy was changed to vancomycin, meropenem
and clarithromycin. PCR for Mycoplasma pneumoniae
from a nasopharyngeal aspirate and urinary Legionella
pneumophila serotype 1 antigen test were negative. On
day 10 of persistent fever, intravenous voriconazole
(6 mg/kg per dose every 12 h on day 1 and 4 mg/kg
every 12 h thereafter) was added to the regimen. High-
resolution computed tomography (HRCT) conﬁrmed
the presence of a consolidation in the left upper lobe
(Fig. 1A), but failed to show a cavitary lesion, a ‘‘halo’’
sign or an ‘‘air-crescent’’ sign. Sonography of the
abdomen was normal. On day 13, the WBC count rose
to 4.4·109/l (neutrophils 2.2·109/l) and the CRP was
175 mg/l. Serum galactomannan assays (Platelia
Aspergillus, Bio-Rad) were negative on days 12, 18 and
24. On day 17, vancomycin and clarithromycin were
discontinued. On day 19, the patient became afebrile and
a HRCT scan demonstrated a decreased size of the
consolidation. On discharge (day 26), the WBC was
6.8·109/l (neutrophils 5.8·109/l) and the CRP level was
20 mg/l. Voriconazole was continued orally for 4 weeks
(until day 52). On day 36, post-chemotherapy evaluation
demonstrated a small, persistent pulmonary lesion in the
left upper lobe by HRCT. Positron emission tomogra-
phy (PET) revealed a focal splenic lesion, which was
conﬁrmed by a repeat PET scan on day 52. Open spleen
biopsy on day 61 showed granulomatous inﬂammation
with fungal elements. Hyphal morphology suggested
zygomycosis. Fungal cultures remained negative. Lipo-
somal amphotericin B (Ambisome) was started at 3 mg/
kg per day on day 66 and increased to 10 mg/kg per day
on day 77. On day 76, an episode of haemoptysis
occurred. HRCT showed a parenchymal abscess of 3 cm
in diameter adjacent to the left hilus (Fig. 1B) and
bronchoscopy revealed a 3 mm, round, ulcerated plaque
in the left upper lobe bronchus. Bronchoalveolar lavage
Fig. 1 HRCT of the lung. A Extensive left upper lobe inﬁltration
on day 10. B A left hilar pulmonary abscess with inclusions of air
(day 76). C Follow-up HRCT performed on day 110 shows
residual changes following partial left upper lobe resection on day
81
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(BAL) fungal cultures remained negative. Partial left
upper lobe resection was performed on day 81. Zygo-
mycosis was conﬁrmed on a pulmonary biopsy specimen
by histology (Fig. 2) and by broad-range fungal PCR
targeting the 28S rRNA gene performed on DNA ex-
tracted from the embedded tissue. DNA sequencing of
the ampliﬁed 28S rRNA fragment identiﬁed Absidia
corymbifera. Fungal culture was negative. Follow-up
HRCT and PET (both on day 92, 110 and 173) showed a
gradually resolving pulmonary inﬁltrate (Fig. 1C) and
persistent splenomegaly without focal lesions. On day
111, antifungal therapy was changed to oral cyclodex-
trine-itraconazole (5 mg/kg once daily) for an additional
4 months.
Discussion
We describe the case of an immunocompromised child
with disseminated A. corymbifera infection during
empirical voriconazole treatment for prolonged febrile
neutropenia. Recovery of two bacterial pathogens from
blood cultures and early clinical improvement during
treatment with antibacterial agents and voriconazole
suggested that the initial pulmonary inﬁltrate was caused
by a bacterial pathogen or a fungus susceptible to
voriconazole (e.g. Aspergillus spp.), and that subsequent
zygomycosis was a true breakthrough infection. Alter-
natively, occult zygomycosis could have been present
from the beginning and temporary clinical improvement
the result of concomitant bone marrow recovery. The
term ‘‘breakthrough’’ infection is also applicable to this
scenario [1]. Irrespective of the sequence of events,
standard dose voriconazole failed to either treat or
prevent A. corymbifera infection in this patient.
Voriconazole demonstrates broad-spectrum antifungal
activity in vitro. Zygomycetes, however, are mostly
resistant [8]. Limited clinical evidence in adults indicates
that voriconazole may also be ineﬀective against zygo-
mycetes in vivo. As mentioned above, voriconazole and
liposomal amphotericin B were compared in a recent
multicentre trial of antifungal therapy in febrile neu-
tropenia in adults [17]. Breakthrough invasive fungal
infections occurred signiﬁcantly less frequently in the
voriconazole group, but there were two cases of zygo-
mycosis in the voriconazole group and none in the
liposomal amphotericin B group. Overall, voriconazole
failed to demonstrate statistical equivalence to liposomal
amphothericin B. Consequently, voriconazole was not
approved by the United States Food and Drug
Administration for empirical therapy of persistent fever
during neutropenia. Failure of intravenous voriconazole
in zygomycosis caused by Cunninghamella berthollettiae
had previously been described in a 33-year-old male with
acute myeloblastic leukaemia [12]. More recently, four
cases of breakthrough zygomycosis in adult patients
with allogeneic haematopoietic stem-cell transplants,
who received voriconazole either as prophylaxis or
empirical treatment, were reported from a single insti-
tution in the United States where zygomycoses were
rarely seen before the advent of voriconazole [10]. A
similar cluster of four cases of zygomycoses was
reported from a transplant unit in France [2].
Here we report the ﬁrst case of zygomycosis being
diagnosed during voriconazole treatment in a child. The
responsible organism, the ubiquitous mould A. cor-
ymbifera, has occasionally been implicated as a patho-
gen in immunocompromised children (Table 1). The
reported locations of A. corymbifera infection in these
cases were the nose, sinuses and skin. All patients were
treated with conventional (1 mg/kg per day) or liposo-
mal (1–15 mg/kg per day) amphotericin B. Two of
ﬁve patients died, although death was attributable to
A. corymbifera infection in one patient only. These cases
are unlikely to reﬂect the entire spectrum of invasive
A. corymbifera infection in children because fungal cul-
ture is insensitive for detection of zygomycetes in tissue
specimens and BAL ﬂuid. It is thus likely that many
cases remain undiagnosed. The present case emphasises
that nucleic acid detection methods such as pathogen-
speciﬁc and broad-range fungal PCR followed by DNA
sequencing of the ampliﬁed fragment may be useful
tools for diagnosing zygomycoses. Documentation of
A. corymbifera infection in our patient provided the
rationale for continuing high-dose liposomal ampho-
tericin B and oﬀered the opportunity for switching to
oral itraconazole, which exhibits in vitro activity against
this particular organism [3, 8]. Posaconazole would have
been an alternative. This investigational azole has
excellent in vitro activity against most zygomycetes
including Rhizopus spp. [3], and both experimental [4]
and anecdotal clinical evidence [14] suggest eﬃcacy
in vivo. No dosage recommendations are currently
available for children.
Fig. 2 The lumen of a bronchus (arrow) and the corresponding
pulmonary artery (arrowhead) are occluded by loose aggregates of
hyphae, visible in the insert. To the left of the pulmonary artery, the
alveolar scaﬀold (asterisk) is less well delineated than to its right
(double asterisk), corresponding to a necrotic area (silver methena-
mine stain, bar = 1000lm). Insert: note the irregular diameter,
the rare septa (arrow) and the nearly rectangular branching
(arrowhead) of the thin-walled hyphae (silver methenamine stain,
bar = 10 lm)
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Voriconazole is an attractive agent for empirical
antifungal therapy. This case, however, demonstrates
that its lack of activity against zygomycetes is clinically
relevant not only in adults, but also in children. More-
over, the case emphasises that aggressive diagnostic
measures (e.g. BAL and tissue biopsy) for identiﬁcation
of a causative organism remain critical in prolonged
febrile neutropenia with a pulmonary inﬁltrate, even if
the obvious advantages of voriconazole encourage its
empirical use. Finally, the case illustrates that cases of
clinical failure of voriconazole should be investigated
thoroughly for the possibility of zygomycosis, ideally by
applying broad-range fungal PCR in culture-negative
patients.
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